Take a look at the beta version of dw.com. We're not done yet! Your opinion can help us make it better.
Initial data (that has yet to be peer reviewed) suggests the BioNTech-Pfizer vaccine may work even better for young teens than it does for adults — due to an even stronger antibody reaction. The announcement came a day after Germany halted the use of AstraZeneca for anyone under 60.